tiprankstipranks
Advertisement
Advertisement

NUVL Stock Latest News

Nuvalent Earns Buy Rating on De-Risked Late-Stage Pipeline and Multi-Launch Potential Through 2026
RatingsNuvalent Earns Buy Rating on De-Risked Late-Stage Pipeline and Multi-Launch Potential Through 2026
8m ago
NUVL
Nuvalent: Buy Rating Reiterated on Strong Oncology Pipeline, Commercial Readiness, and Unchanged $142 Price Target
PremiumRatings
Nuvalent: Buy Rating Reiterated on Strong Oncology Pipeline, Commercial Readiness, and Unchanged $142 Price Target
2h ago
NUVL
Nuvalent reports Q1 EPS ($1.39), consensus ($1.31)
PremiumThe Fly
Nuvalent reports Q1 EPS ($1.39), consensus ($1.31)
9h ago
NUVL
Guardant Health announces multi-year strategic collaboration with Nuvalent
PremiumThe Fly
Guardant Health announces multi-year strategic collaboration with Nuvalent
7d ago
GH
NUVL
Nuvalent Buy Rating: Zidesamtinib’s Differentiated ROS1 CNS Efficacy Supports $155 Target Price
PremiumRatings
Nuvalent Buy Rating: Zidesamtinib’s Differentiated ROS1 CNS Efficacy Supports $155 Target Price
16d ago
NUVL
Nuvalent to present preclinical data for zidesamtinib at AACR meeting
PremiumThe FlyNuvalent to present preclinical data for zidesamtinib at AACR meeting
20d ago
NUVL
Nuvalent: Buy Rating on Strong Pipeline Execution, Dual NDA Momentum, and Solid Cash Runway in Targeted NSCLC
Premium
Ratings
Nuvalent: Buy Rating on Strong Pipeline Execution, Dual NDA Momentum, and Solid Cash Runway in Targeted NSCLC
1M ago
NUVL
Nuvalent Files FDA Application for Lung Cancer Therapy
Premium
Company Announcements
Nuvalent Files FDA Application for Lung Cancer Therapy
1M ago
8K
NUVL
Nuvalent submits neladalkib NDA to FDA
PremiumThe Fly
Nuvalent submits neladalkib NDA to FDA
1M ago
NUVL
Nuvalent initiated with an Overweight at Wells Fargo
PremiumThe Fly
Nuvalent initiated with an Overweight at Wells Fargo
1M ago
NUVL
De-Risked Oncology Pipeline and Strong Cash Position Underpin Outperform Rating and $125 Target
PremiumRatings
De-Risked Oncology Pipeline and Strong Cash Position Underpin Outperform Rating and $125 Target
2M ago
NUVL
Nuvalent price target raised to $138 from $132 at UBS
PremiumThe Fly
Nuvalent price target raised to $138 from $132 at UBS
2M ago
NUVL
Nuvalent: Buy Rating Backed by Late‑Stage Oncology Pipeline and Upcoming Value‑Driving Milestones
PremiumRatingsNuvalent: Buy Rating Backed by Late‑Stage Oncology Pipeline and Upcoming Value‑Driving Milestones
2M ago
NUVL
Nuvalent price target raised to $140 from $135 at Cantor Fitzgerald
Premium
The Fly
Nuvalent price target raised to $140 from $135 at Cantor Fitzgerald
2M ago
NUVL
Nuvalent reports Q4 EPS ($1.58), consensus ($1.44)
Premium
The Fly
Nuvalent reports Q4 EPS ($1.58), consensus ($1.44)
2M ago
NUVL
Nuvalent files automatic mixed securities shelf
PremiumThe Fly
Nuvalent files automatic mixed securities shelf
5M ago
NUVL
Nuvalent price target lowered to $145 from $147 at JPMorgan
PremiumThe Fly
Nuvalent price target lowered to $145 from $147 at JPMorgan
5M ago
NUVL
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
5M ago
FHTX
NUVL
Nuvalent’s Royalty Interest Acquired by Royalty Pharma
PremiumCompany Announcements
Nuvalent’s Royalty Interest Acquired by Royalty Pharma
5M ago
8K
NUVL
Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
PremiumThe FlyRoyalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
5M ago
NUVL
RPRX
Ron Squarer Joins Nuvalent Board as Independent Director
Premium
Company Announcements
Ron Squarer Joins Nuvalent Board as Independent Director
5M ago
8K
NUVL
Nuvalent initiated with a Buy at Truist
Premium
The Fly
Nuvalent initiated with a Buy at Truist
5M ago
NUVL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >